Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
View Patent ↗The present invention relates generally to the production of recombinant human uteroglobin (rhUG) for use as a therapeutic in the treatment of inflammation and fibrotic diseases. More particularly, the invention provides processes, including broadly the steps of bacterial expression and protein purification, for the scaled-up production of rhUG according to current Good Manufacturing Practices (cGMP). The invention further provides analytical assays for evaluating the relative strength of in vivo biological activity of rhUG produced via the scaled-up cGMP processes.
1. A method of purifying rhUG comprising the steps of:
a. providing a bacterial cell paste comprising bacterial cells capable of overexpressing rhUG;
b. lysing the bacterial cell paste and pelleting the debris to form a supernatant;
c. filtering the supernatant formed in step b through a first nominal molecular weight cut off membrane to form a first permeate;
d. concentrating the first permeate formed in step c by the use of a second nominal molecular weight cut off membrane;
e. loading the concentrated permeate formed in step d onto an anion exchange column to form a first eluate;
f. concentrating the first eluate formed in step e by the use of a third nominal molecular weight cut off membrane to form a second concentrate;
g. loading the second concentrate formed in step f onto a hydroxyapatite column to form a second eluate;
h. separating host-derived proteins from the rhUG in the second eluate formed in step g to provide purified rhUG; and
i. recovering the purified rhUG formed in step h.
2. The method of claim 1 , wherein lysing comprises shearing.
3. The method of claim 1 , wherein between step b and step c, cell debris is removed by centrifugation.
4. The method of claim 1 , wherein the membrane of step b is about a 30K to 100K nominal molecular weight cut off membrane.
5. The method of claim 4 , wherein the filtering of step c comprises the use of a tangential flow filtration system.
6. The method of claim 1 , wherein the membrane of step d is about a 5K nominal molecular weight cut off membrane.
7. The method of claim 6 , wherein the host-derived proteins of step h are separated with a chelating fast flow resin column.
8. The method of claim 7 , wherein the chelating fast flow resin column comprises copper.
9. The method of claim 8 , wherein after step h a positively charged membrane is placed downstream of the chelating fast flow resin column forming a pass through substantially free of host derived proteins.
10. The method of claim 9 , wherein the positively charged membrane is a filtration membrane.
11. The method of claim 1 , wherein the second eluate is diafiltered through about a 30K nominal molecular weight cut off membrane.
12. The method of claim 1 , wherein the rhUG recovered in step i is substantially free of aggregates.
13. A method of purifying rhUG comprising the steps of:
a. providing bacterial cells capable of overexpressing rhUG;
b. lysing the bacterial cells and pelleting the debris to form a supernatant liquid;
c. filtering the liquid through a nominal molecular weight cut off membrane;
d. loading the liquid onto an ion exchange column;
e. separating host-derived proteins from the rhUG to provide purified rhUG; and
f. recovering the purified rhUG
wherein the level of endotoxin in said rhUG is less than 5 EU/mg.
14. The method of claim 13 , wherein the filtering of step c comprises the use of a tangential flow filtration system.
15. The method of claim 13 , wherein the host-derived proteins of step e are separated with a chelating fast flow resin column.
16. The method of claim 13 , wherein the rhUG recovered in step f is substantially free of aggregates.